A Multicenter, Randomized, Double-blind, Active-controlled, 2 Week Treatment, Parallel-group Study to Assess the Efficacy and Safety of Indacaterol Acetate Delivered Via the Concept1 Inhalation Device in Children Greater or Equal to 6 and Less Than 12 Years of Age With Asthma
Phase of Trial: Phase II
Latest Information Update: 17 May 2017
At a glance
- Drugs Indacaterol (Primary)
- Indications Asthma
- Focus Therapeutic Use
- Sponsors Novartis Pharmaceuticals
- 11 May 2017 Planned End Date changed from 1 Feb 2018 to 17 Apr 2018.
- 11 May 2017 Status changed from not yet recruiting to recruiting.
- 24 Sep 2016 New trial record